¿¡¸¦·ÎƼ´Õ°ú ¶óÆÄƼ´ÕÀ» »ç¿ëÇÑ È¯ÀÚ¿¡¼­ ¹ß»ýÇÑ Ç¥ÃþÁ¡»ó°¢¸·º´Áõ
Superficial Punctate Keratoepitheliopathy Under Treatment with Erlotinib and Lapatinib

´ëÇѾȰúÇÐȸÁö 2014³â 55±Ç 2È£ p.293 ~ p.297

¿ÀÀº±Ô(Oh Eun-Kyu) - ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¾È°úÇб³½Ç
Á¶µ¿Çö(Jo Dong-Hyun) - ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¾È°úÇб³½Ç
±è¹Ì±Ý(Kim Mee-Kum) - ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¾È°úÇб³½Ç
À§¿ø·®(Wee Won-Ryang) - ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¾È°úÇб³½Ç

Abstract

¸ñÀû: Ç×¾Ï Ä¡·á·Î Ç¥ÇǼºÀåÀÎÀÚ¼ö¿ëü ¾ïÁ¦Á¦(¿¡¸¦·ÎƼ´Õ, ¶óÆÄƼ´Õ)¸¦ »ç¿ëÇÑ È¯ÀÚ¿¡¼­ Ç¥ÃþÁ¡»ó°¢¸·º´Áõ 2¿¹¸¦ °æÇèÇÏ¿© ¹®Çå°íÂû °ú ÇÔ²² º¸°íÇÏ°íÀÚ ÇÑ´Ù.

Áõ·Ê¿ä¾à: Áõ·Ê 1Àº ¿¡¸¦·ÎƼ´ÕÀ» »ç¿ëÇÑ ÈÄ °¢¸·Á¢ÃËÀÌ ¾ø´Â °Å´ë ¼Ó´«½çÁõ°ú ¹Ì¸¸¼ºÀÇ Ç¥ÃþÁ¡»ó°¢¸·º´ÁõÀÌ ¹ß»ýÇÏ¿´´Ù. °¢¸·º´ÁõÀº ¿¡¸¦·ÎƼ´ÕÀ» Áß´ÜÇÑ ÈÄ È£ÀüµÇ¾ú°í, ¿¡¸¦·ÎƼ´ÕÀ» ´Ù½Ã »ç¿ëÇÑ ÀÌÈÄ Àç¹ßÇÏ¿´´Ù. Áõ·Ê 2´Â ¶óÆÄƼ´ÕÀ» »ç¿ëÇÑ ÈÄ ¼Ó´«½çÀÇ º¯È­¾øÀÌ ¹Ì¸¸¼ºÀÇ Ç¥ÃþÁ¡»ó°¢¸·º´ÁõÀÌ ¹ß»ýÇÏ¿´´Ù. µÎ Áõ·Ê ¸ðµÎ ½É°¢ÇÑ ½Ã·ÂÀúÇÏ´Â ¾ø¾ú°í, ¹«¹æºÎÁ¦Àΰø´©¾×°ú ÀÚ°¡Ç÷û¾È¾àÀ» »ç¿ëÇÏ°í È£ ÀüµÇ¾ú´Ù.

°á·Ð: ¿¡¸¦·ÎƼ´Õ°ú ¶óÆÄƼ´ÕÀÌ ¹Ì¸¸¼ºÀÇ Ç¥ÃþÁ¡»ó°¢¸·º´ÁõÀ» À¯¹ßÇÑ °ÍÀ¸·Î »ý°¢ÇÏ°í, Á¡¾È¾× »ç¿ëÀ¸·Î È£ÀüµÇ¾ú´Ù.
Purpose: To report the corneal superficial punctate keratoepitheliopathy in 2 patients taking the epidermal growth factor receptor (EGFR) inhibitors, erlotinib and lapatinib, respectively.

Case summary: Case 1, who received erlotinib, showed trichomegaly without touching the cornea and diffuse punctate keratoepitheliopathy. Corneal epitheliopathy and the corresponding symptoms resolved after discontinuation of the drug then recurred with reapplication. Case 2 presented diffuse corneal punctate epithelial erosions that developed without any cilia involvement after the patient was administered lapatinib. The visual acuity of both patients was not severely diminished and keratoepitheliopathy was mostly resolved with the treatment of preservative-free artificial tears and autologous serum eye drops.

Conclusions: Erlotinib and lapatinib are both likely to cause visually tolerable corneal punctate keratoepitheliopathy which can be resolved with appropriate topical treatment.

Å°¿öµå

Cancer treatment, Corneal erosion, Epidermal growth factor
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå